- Nearly 4 out of 5 people treated for the first time cleared the virus with INCIVEK combination treatment - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has approved INCIVEK™ (telaprevir) tablets for a broad group of
-- Approximately 100 people in Canada have the G551D mutation in the CFTR gene -- -- First medicine resulting from 1989 co-discovery of CF gene by researchers in Canada and the U.S. -- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that
-Approximately 1,500 people in Canada are ages 12 and older and have two copies of the F508del mutation, the most common genetic form of the disease- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has approved Pr ORKAMBI ®
-SYMDEKO is Vertex’s third medicine to treat the underlying cause of CF- -Approximately 2,000 people in Canada are ages 12 and older and have two copies of the F508del mutation or at least one mutation in the CF gene that is responsive to treatment with SYMDEKO- BOSTON --(BUSINESS WIRE)--Jun.
-KALYDECO is the first and only approved medicine in Canada to treat the underlying cause of cystic fibrosis in these young patients- BOSTON --(BUSINESS WIRE)--Jan. 28, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Market Authorization for
- ORKAMBI is the first medicine in Canada to treat the underlying cause of CF in young children with two copies of the F508del mutation - BOSTON --(BUSINESS WIRE)--Dec. 13, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that Health Canada has granted Market Authorization
-Approximately 500 Canadians ages 6-11 are now eligible for TRIKAFTA ® - - Vertex has submitted this indication to CADTH & INESSS for Health Technology Assessments- BOSTON --(BUSINESS WIRE)--Apr. 20, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has
-Approximately 1,100 F/MF patients now eligible for a CFTR modulator to treat the underlying cause of their disease- BOSTON --(BUSINESS WIRE)--Jun. 18, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced Health Canada has granted Marketing Authorization for TRIKAFTA ®
<i>-VX-222 was well-tolerated across all four dose groups through three
days of dosing, with all adverse events being mild to moderate in
severity-</i>
<br />
<i>-Greater than 3 log</i><sub><i>10 </i></sub><i>reduction in HCV RNA
observed across all four VX-222 dose groups-</i>
<br />
<i>-Results support previously announced Phase 2 proof-of-concept
clinical trial evaluating VX-222 in combination with Vertex's lead HCV
protease inhibitor telaprevir-</i>
<br />
